Newly developed retatrutide, a combined-action treatment targeting simultaneously GLP-1 and GIP receptors, is creating considerable interest within the weight loss community. Preliminary clinical studies have revealed substantial losses in overall size and gains in physiological markers for patients with excess weight . Researchers believe this… Read More